Сорбенты для экстракорпорального удаления токсических веществ и молекул с нежелательной биологической активностью (обзор)
https://doi.org/10.15360/1813-9779-2016-6-82-107
Аннотация
В обзоре рассмотрены сорбенты и медицинские изделия на их основе, применяемые в клинической практике для экстракорпоральной детоксикации с помощью процедуры гемосорбции. Представлены данные исследователей, свидетельствующие об эффективности такого подхода с целью удаления бактериальных эндотоксинов, липопротеинов низкой плотности, билирубина, а также при лечении аутоиммунных заболеваний. Основное внимание уделено применению гемосорбции при лечении тяжелого сепсиса и септического шока. Обосновывается необходимость разработки и применения новых «мультимодальных» сорбентов, сочетающих свойства как «селективных», так и «неселективных» сорбентов. В обзоре приведены сведения о клинической эффективности гемосорбции и молекулярном взаимодействии сорбента с циркулирующими молекулами, патогенетически значимыми для развития критических состояний и тяжелых заболеваний. Библиография — 137 ссылок.
Ключевые слова
Об авторах
А. С. Морозов
АО Перспективные медицинские технологии
Россия
107045, г. Москва, Луков пер., д. 4, оф. 8
Россия
107045, г. Москва, Луков пер., д. 4, оф. 8
И. В. Бессонов
АО Перспективные медицинские технологии
Россия
107045, г. Москва, Луков пер., д. 4, оф. 8
Россия
107045, г. Москва, Луков пер., д. 4, оф. 8
А. В. Нуждина
Московский государственный технический университет им. Н. Э. Баумана
Россия
105005, г. Москва, 2-я Бауманская ул., д. 5, стр. 1
Россия
105005, г. Москва, 2-я Бауманская ул., д. 5, стр. 1
В. М. Писарев
НИИ общей реаниматологии им. В. А. Неговского
Россия
107031, г. Москва, ул. Петровка, д. 25, стр. 2
Россия
107031, г. Москва, ул. Петровка, д. 25, стр. 2
Список литературы
1. Toshiaki I. Hemoadsorption in critical care. Ther. Apher. 2002; 6 (3): 189–192. http://dx.doi.org/10.1046/j.15260968.2002.00430.x.PMID: 12109941
2. Winchester J.F., Ronco C., Brady J.A., Clemmer J., Muller T.E., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Levin N.W. History of sorbents in uremia. Contrib. Nephrol. 2001; 133: 131–139. http://dx.doi.org/10.1159/000060120. PMID: 11477746
3. Ash S.R. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace Ther. 2002; 9 (1): 3–18. http://dx.doi.org/10.1053/jarr.2002.30474. PMID: 11927902
4. Winchester J.F., Salsberg J.A. Sorbents in the treatment of renal failure. Minerva Urol. Nefrol. 2004; 56 (3): 215–221. PMID: 15467500
5. Shoji H., Tani T., Hanasawa K., Kodama M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther. Apher. 1998; 2 (1): 3–12. http://dx.doi.org/10.1111/j.17449987.1998.tb00066.x.PMID: 10227782
6. Ronco C. Endotoxin removal: history of a mission. Blood Purif. 2014; 37 (Suppl 1): 5–8. http://dx.doi.org/10.1159/000356831. PMID: 24457488
7. Ash S.R. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs. 1994; 18 (5): 355–362. http://dx.doi.org/10.1111/j.15251594.1994.tb02216.x. PMID: 8037609
8. Mitzner S.R., Stange J., Klammt S., Peszynski P., Schmidt R., Noldge Schomburg G. Extracorporeal detoxification using molecular adsorbent recirculating system for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12 (Suppl 17): S75–S82. PMID: 11251037
9. Winchester J.F., Ronco C., Brady J.A., Cowgill L.D., Salsberg J., Yousha E., Choquette M., Albright R., Clemmer J., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Cohen G., HörlW., Gotch F., Levin N.W. The next step from highflux dialysis: application of sorbent technology. Blood Purif. 2002; 20 (1): 81–86. http://dx.doi.org/10.1159/000046989. PMID: 11803163
10. Geiger H., Klepper J., Lux P., Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR350) in critically ill patients with intractable jaundice. Int. J. Artif. Organs. 1992; 15 (1): 35–39. PMID: 1551726
11. Tabei K., Akai Y., Takeda S., Homma S., Kusano E., Asano Y. Application of plasma perfusion in hepaticfailure. Biomater. Artif. Cells Immobilization Biotechnol. 1991; 19 (1): 193–201. http://dx.doi.org/10.3109/10731199109117826. PMID: 1751670
12. Mikhalovsky S.V. Microparticles for hemoperfusion and extracorporeal therapy. In: Arshady R. (ed.). Microspheres, microcapsules and liposomes. The MML Series, vol. 2: medical & biotechnology applications. London: Citus Books; 1999: 133–169.
13. Gordon A., Lewin A.J., Maxwell M.H., Roberts M. Current status of dialysate regeneration for the treatment of chronic uremia. In: Chang T.M.S. (ed.). Artificial kidney, artificial liver, and artificial cells. N.Y.: Plenum Press; 1978: 23–32. http://dx.doi.org/10.1007/9781468424782_4
14. Sangster B., van Heijst A.N.P., Sixma J.J. The influence of hemoperfusion on hemostasis and cellular constituents of the blood in the treatment of intoxications — a comparative study of 3 types of columns (Haemocol, Amberlite XAD4, Gambro Adsorba 300oC). Arch. Toxicol. 1981; 47 (4): 269–278. http://dx.doi.org/10.1007/bf00332393. PMID: 7271453
15. Clark W.T., III. Biocompatible hemoperfusion system. United States patent US4048064 (USA). 1977 Sept 13.
16. Cerulli N., La Greca G., Laville M., Palla R., Ramello A., Ghezzi P.M., Fouque D., Pizzarelli F., Schena F.P., Tetta C., Buades J., Camussi G., David S., Hoerl W., Triolo G., Maggiore U., Chiarulli G., Losurdo N., Petrarulo F., Sacchetti A., Pallotta G., Dagostino F., Del Mastro G., Sasdelli M., Mura C., Bongiorno P., Grill A., Varvara M., Carabellese S., Laraia E., Rizzi R., Mancini A., Losappio R., Maiorca R., Movilli E., Scolari F., Fiorini F., Imperatore P., Ranieri F., Bozzi M., Cuzzola R., De Min A., Specchio A., Bonomini M., Cuonzo M.T., Di Bari M., Dogliani M., Fidelio T., Ghezzi P.M., Meinero S., Canepari G., Surian M., Bonforte G., Rivera R., Sangalli L., Broccoli R., Maggiore Q., Pizzarelli F., Cavatorta F., Zollo A., Mastrangelo F., De Blasi V., Alfonso L., Usberti M., Rondina M., Laville M., Fouque D., Combarnous F., Basile C., Giordano R., Palla R., Betti G., Lopez T., Casino F., Ponticelli C., Valenti G., Ambroso G., Como G., di Belgioioso G.B., Bertoli S., Buzzi L., Albertazzi A., Lucchi L., Virgilio M., Giancaspro V., Pastore G., Conversano A., Testa A., Malcangi U., Reina E., Rusconi L., Meterangelis A., Amato M., Campolo G., Giachino G., Chiappero F., Carozzi S., Schelotto C., Sanna A., Stallone C., Aucella F., Ramello A., Marangella M., Vitale C., Quarello F., Formica M., Gastaldi L., Frattini G.M., Ervo R., Mij M., Baroni A., Borzumati M., Maschio G., Tessitore N., Loschiavo C., La Greca G., Brendolan A., Sessa A., Conte F., Ancarani E., Costantini S., Galliani M., Lorenz M., Robba C. The effect of hemodiafiltration with online endogenous reinfusion (online HFR) on anemia: design of a European, open, randomised, multicentre trial. J. Nephrol. 2000; 13 (1): 34–42. PMID: 10720212
17. Falkenhagen D., Strobl W., Hartmann T., Schrefl A., Linsberger I., Kellner K.H., Aussenegg Z., Leitner A. Patient safety technology extracorporeal for microadsorbent systems in blood purification. Artif. Organs. 2002; 26 (2): 84–90. http://dx.doi.org/10.1046/j.15251594.2002.06884.x. PMID: 11879234
18. Yu Y.T., Chen C.Z. Advances of adsorbents for hemoperfusion in China. Biomater. Artif. Cells Artif. Organs. 1990; 18 (4): 499–505. http://dx.doi.org/10.3109/10731199009119624. PMID: 2285812
19. Bansal R.C., Donnet J.B., Stoeckli F. (eds.). Active carbon. N.Y.: Marcel Dekker; 1988: 482.
20. Cipoletti J.J. Resin technology in medicine. In: Cipoletti J.J., Kunin R., Meyer F. Sorbents and their clinical applications. N.Y.: Academic Press; 1980: 221–248.
21. Афанасьева O.K., Алтынова Е.В., Болдырев А.Г., Соколов А.А., Адамова И.Ю., Покровский С.H. Сравнительный анализ эффективности и специфичности разных сорбентов для афереза липопротеидов низкой плотности. Бюл. эксперим. биологии и медицины. 2006; 142 (11): 532–536. http://dx.doi.org/10.1007/s1051700604254. PMID: 17415469
22. Yokoyama S., Hayashi R., Satani M., Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholes terolemia. Arteriosclerosis. 1985; 5 (6): 613–622. http://dx.doi.org/10.1161/01.atv.5.6.613. PMID: 3865648
23. Koll R.A. LDLTherasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther. Apher. 1998; 2 (2): 142–146. http://dx.doi.org/10.1111/j.17449987.1998.tb00092.x. PMID: 10225716
24. Bosch T. Recent advances in therapeutic apheresis. J. Artif. Organs. 2003; 6 (l): 1–8. http://dx.doi.org/10.1007/s100470300000. PMID: 14598117
25. Thompson G.R. LDL apheresis. Atherosclerosis. 2003; 167 (1): 1–13. http://dx.doi.org/10.1016/s00219150(02)002514. PMID: 12618263
26. NewsomDavis J. Autoimmunity in neuromuscular disease. Ann. N. Y. Acad. Sci. 1988; 540: 25–38. http://dx.doi.org/10.1111/j.17496632.1988.tb27048.x. PMID: 2849891
27. Bradl M., Lassmann H. Neurologic autoimmunity: mechanisms revealed by animal models. Handb. Clin. Neurol. 2016; 133: 121–143. http://dx.doi.org/10.1016/B9780444634320.000086. PMID: 27112675
28. Gilhus N.E., Skeie G.O., Romi F., Lazaridis K., Zisimopoulou P., Tzartos S. Myasthenia gravis — autoantibody characteristics and their implica tions for therapy. Nat. Rev. Neurol. 2016; 12 (5): 259–268. http://dx.doi.org/10.1038/nrneurol.2016.44. PMID: 27103470
29. Von Thun Und HohensteinBlaul N., Bell K., Pfeiffer N., Grus F.H. Autoimmune aspects in glaucoma. Eur. J. Pharmacol. 2016; 787: 105–118. http://dx.doi.org/10.1016/j.ejphar.2016.04.031. PMID: 27090926
30. Lally L., Sammaritano L.R. Vasculitis in antiphospholipid syndrome. Rheum. Dis. Clin. North Am. 2015; 41 (1): 109–123. http://dx.doi.org/10.1016/j.rdc.2014.09.009. PMID: 25399943
31. Conigliaro P., Chimenti M.S., Triggianese P., Sunzini F., Novelli L., Perricone C., Perricone R. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 2016; 15 (7): 673–683. http://dx.doi.org/10.1016/j.autrev.2016.03.003. PMID: 26970491
32. Sueoka A. Present status of apheresis technologies, part 3: adsorbent. Ther. Apher. 1997; 1 (3): 271–283. http://dx.doi.org/10.1111/j.17449987.1997.tb00150.x. PMID: 10225751
33. Hashimoto H., Tsuda H., Kanai Y., Kobayashi S., Hirose S., Shinoura H., Yokohari R., Kinoshita M., Aotsuka S., Yamada H., Takahashi K., Yoshiyama S., Miyamoto T. Selective removal of antiDNA and anticar diolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J. Rheumatol. 1991; 18 (4): 545–551. PMID: 2066947
34. Wiesenhuter C., Irish B., Bertram J. Treatment of patients with refractory rheumatoid arthritis with extracorporeal proteinA immunoadsorption column: a pilot trial. J. Rheumatol. 1994; 21 (5): 804–812. PMID: 8064718
35. Falson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., Deal C., Evance S., Fleischmann R., Gendreau R.M., Harris E.R., Matteson E.L., Roth S.H., Schumacher H.R., Weisman M.H., Furst D.E. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, doubleblind, shamcontrolled trial. Arthritis. Rheum. 1999; 42 (10): 2153–2159. http://dx.doi.org/10.1002/15290131(199910)42:10<2153::aidanr16>3.0.co;2w. PMID: 10524687
36. Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher. 1999; 3 (3): 240– 245. http://dx.doi.org/10.1046/j.15260968.1999.00155.x. PMID: 10427622
37. Oka K., Nakaji S., Tanihara M., Takakura K., Takamori M. Development of specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. Jpn. J. Artif. Organs. 1993; 22: 194–197.
38. Nakaji S., Oka K., Tanihara M., Takakura K., Takamori M. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993. Ther. Apher. 2000; 4 (2): 124–126. http://dx.doi.org/10.1046/j.15260968.2000.004002124.x. PMID: 10805430
39. Koll R.A. IgTherasorb immunoadsorption for selective removal of human immunoglobulin diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 1998; 2 (2): 147–152. http://dx.doi.org/10.1111/j.17449987.1998.tb00093.x. PMID: 10225717
40. Kutsuki H., Takata S., Yamamoto K., Tani N. Therapeutic selective adsorption of antiDNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther. Apher. 1998; 2: 18–24. http://dx.doi.org/10.1111/j.17449987.1998.tb00068.x. PMID: 10227784
41. Pokrovsky S., Kuznetsova Yu.V., Afanasieva O.I., Zvezdkin P.V., Adamova I. Yu., Konovalov G.A. Clinical experience of immunoadsorption with ‘Ig Adsopak’ columns. Ther. Apher. Dial. 2005; 9 (5): A38. http://dx.doi.org/10.1111/j.17449987.2005.00324_4.x
42. Zahir F., Rabbani G., Khan R.H., Rizvi S.J., Jamal M.S., Abuzenadah A.M. The pharmacological features of bilirubin: the question of the century. Cell Mol. Biol. Lett. 2015; 20 (3): 418–447. http://dx.doi.org/10.1515/cmble20150012. PMID: 26208389
43. Qaisiya M., Brischetto C., Jašprová J., Vitek L., Tiribelli C., Bellarosa C. Bilirubininduced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Arch. Toxicol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s0020401618353. PMID: 27578021
44. Ahlfors C. Plasma bilirubin binding and bilirubin neurotoxicity. Dev. Med. Child Neurol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1111/dmcn.13303. PMID: 27786370
45. Riordan S.M., Bittel D.C., Le Pichon J.B., Gazzin S., Tiribelli C., Watchko J.F., Wennberg R.P., Shapiro S.M. A hypothesis for using pathway genetic load analysis for understanding complex outcomes in bilirubin encephalopathy. Front Neurosci. 2016; 10: 376. http://dx.doi.org/10.3389/fnins.2016.00376. PMID: 27587993
46. Watchko J.F. Bilirubininduced neurotoxicity in the preterm neonate. Clin. Perinatol. 2016; 43 (2): 297–311. http://dx.doi.org/10.1016/j.clp.2016.01.007. PMID: 27235209
47. Bhutani V.K., Wong R.J., Stevenson D.K. Hyperbilirubinemia in preterm neonates. Clin. Perinatol. 2016; 43 (2): 215–232. http://dx.doi.org/10.1016/j.clp.2016.01.001. PMID: 27235203
48. Amin S.B., Wang H., Laroia N., Orlando M. Unbound bilirubin and auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice. J. Pediatr. 2016; 173: 84–89. http://dx.doi.org/10.1016/j.jpeds.2016.02.024. PMID: 26952116
49. Wusthoff C.J., Loe I.M. Impact of bilirubininduced neurologic dysfunction on neurodevelopmental outcomes. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 52–57. http://dx.doi.org/10.1016/j.siny.2014.12.003. PMID: 25585889
50. Olusanya B.O. Societal impact of bilirubininduced hearing impairment in resourcelimited nations. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 58–63. http://dx.doi.org/10.1016/j.siny.2014.12.009. PMID:25573775
51. Gazzin S., Vitek L., Watchko J., Shapiro S.M., Tiribelli C. A novel perspective on the biology of bilirubin in health and disease. Trends Mol. Med. 2016; 22 (9): 758–768. http://dx.doi.org/10.1016/j.molmed.2016.07.004. PMID: 27515064
52. Tan H.K. Molecular Adsorbent Recirculating System (MARS). Ann. Acad. Med. Singapore. 2004; 33 (3): 329–335. PMID: 15175774
53. Collins K.L., Roberts E.A., Adeli K., Bohn D., Harvey E.A. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatr. Nephrol. 2008; 23 (6): 1013–1016. http://dx.doi.org/10.1007/s004670080761x. PMID: 18299897
54. Mitzner S., Klammt S., Stange J., Schmidt R. Albumin regeneration in liver supportcomparison of different methods. Ther. Apher. Dial. 2006; 10 (2): 108–117. http://dx.doi.org/10.1111/j.17449987.2006.00351.x.PMID: 16684211
55. Takenaka Y. Bilirubin adsorbent column for plasma perfusion. Ther. Apher. 1998; 2 (2): 129–133. http://dx.doi.org/10.1111/j.17449987.1998.tb00090.x. PMID: 10225714
56. Nakaji S., Hayashi N. Bilirubin adsorption column Medisorba BL300. Ther. Apher. Dial. 2003; 7 (1): 98–103. http://dx.doi.org/10.1046/j.15260968.2003.00007.x. PMID: 12921123
57. Stegmayr B.G. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 1996; 14 (1): 94–101. http://dx.doi.org/10.1159/000170250. PMID: 8718572
58. Stegmayr B.G. Is there a future for adsorption techniques in sepsis? Blood Purif. 2000; 18 (2): 149–155. http://dx.doi.org/10.1159/000014440. PMID: 10838475
59. Rimmelé T., Kellum J.A. Clinical review: blood purification for sepsis. Crit. Care. 2011; 15 (1): 205. http://dx.doi.org/10.1186/cc9411. PMID: 21371356
60. Воинов В.А. Эфферентная терапия критических состояний в реаниматологии. СПб.: СанктПетербургский ГМУ им. И.П.Павлова; 2013: 110.
61. Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect. Dis. 2011; 11 (1): 65–71. http://dx.doi.org/10.1016/s14733099(10)702206. PMID: 21183148
62. Бажина Е.С., Никулин А.В., Хорошилов С.Е. Экстракорпоральные методы лечения абдоминального сепсиса. Общая реаниматология. 2015; 11 (5): 4566. http://dx.doi.org/10.15360/18139779201554566
63. Ушакова Н.Д., Шевченко А.Н., Четвериков М.В., Златник Е.Ю., Зыкова Т.А. Результаты применения селективной адсорбции эндотоксина при сепсисе у онкологических больных. Общая реаниматология. 2014; 10 (6): 32–38. http://dx.doi.org/10.15360/18139779201463238
64. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 2003; 7 (1): 108–114. http://dx.doi.org/10.1046/j.15260968.2003.00005.x.PMID:12921125
65. Nakamura T., Kawagoe Y., Suzuki T., Shoji H., Ueda Y., Koide H. Polymyxin B–immobilized fiber hemoperfusion with the PMX05R column in elderly patients suffering from septic shock. Am. J. Med. Sci. 2007; 334 (4): 244–247. http://dx.doi.org/10.1097/MAJ.0b013e3180a5e8d8. PMID: 18030179
66. Toray Medical Co., Ltd. for endotoxin removal in patients with severe sepsis and septic shock. http://www.toraymedical.com/en/medical/kyusei/pdf/PMX20R.pdf
67. Kojika M., Sato N., Yaegashi Y., Suzuki Y., Suzuki K., Nakae H., Endo S. Endotoxin adsorption therapy for septic shock using polymyxin B immobilized fibers (PMX): evaluation by highsensitivity endotoxin assay and measurement of the cytokine production capacity. Ther. Apher. Dial. 2006; 10 (1): 12–18. http://dx.doi.org/10.1111/j.17449987.2006.00340.x. PMID: 16556131
68. Shoji H., Minaga M., Sakai Y., Kunitomo T., Takeyama T., Tani T., Kodama M. Design and development of endotoxin detoxifying column PMX and its clinical application. Jpn. J. Artif. Organs. 1993; 22 (1): 204–211.
69. Sakai Y., Shoji H., Kobayashi T., Terada R., Sugaya H., Murakami R., Moriyama K., Minaga M., Kunitomo N., Takeyama T. New extracorpo real blood purification devices for critical care medicine under devel opment. Ther. Plasmapheresis. 1993; 12: 837–842.
70. Shimizu T., Obata T., Sonoda H., Akabori H., Tabata T., Eguchi Y., Endo Y., Tani T. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin Bimmobilized fiber columnin patients with septic shock. Transfus. Apher. Sci. 2013; 49 (3): 499–503. http://dx.doi.org/10.1016/j.transci.2013.04.042. PMID: 23683501
71. Jaber B.L., Barrett T.W., Cendoroglo Neto M., Sundaram S., King A.J., Pereira B.J. Endotoxin removal by polymyxinB immobilized polystyrenederivative fibers during in vitro hemoperfusion of 10% human plasma. ASAIO J. 1998; 44 (1): 54–61. http://dx.doi.org/10.1097/0000248019980100000012. PMID: 9466502
72. Tani T., Hanasawa K., Kodama M., Imaizumi H., Yonekawa M., Saito M., Ikeda T., Yagi Y., Takayama K., Amano I., Shimaoka H., Ohta M., Okahisa T., Koga N., Fujita N., Yamasa H. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor1 activities in septic patients. World J. Surg. 2001; 25 (5): 660–668. http://dx.doi.org/10.1007/s002680020028. PMID: 11396436
73. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Maeda S., Yamagishi S. Suppression of highmobility group box1 and receptor for advanced glycation endproduct axis by polymyxin B–immobilized fiber hemop erfusion in septic shock patients. J. Crit. Care. 2011; 26 (6): 546– 549. http://dx.doi.org/10.1016/j.jcrc.2010.11.010. PMID: 21273029
74. Oishi K., MimuraKimura Y., Miyasho T., Aoe K., Ogata Y., Katayama H., Murata Y., Ueoka H., Matsumoto T., Mimura Y. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61 (1): 84–89. http://dx.doi.org/10.1016/j.cyto.2012.08.032. PMID: 23021430
75. Shimizu T., Hanasawa K., Sato K., Umeki M., Koga N., Naganuma T., Sato S., Shimonishi T., Ikeda T., Matsuno N., Ono S., Saitoh H., Satoh K., Otani Y., Endo Y., Eguchi Y., Tani T.; PMX Treatment Study Group in Septic Patients with Colorectal Perforation. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin Bimmobilized fiber column in septic patients with colorectal perforation. Eur. Surg. Res. 2009; 42 (2): 109–117. http://dx.doi.org/10.1159/000187169. PMID: 19122457
76. Hanasawa K., Tani T., Oka T., Yoshioka T., Endo Y., Horisawa M., Nakane Y., Kodama M., Teramoto K., Nishiumi S. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. Ther. Apher. 2000; 4 (2): 142–145. http://dx.doi.org/10.1046/j.15260968.2000.004002142.x. PMID: 10805433
77. Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M., Uchiyama Y., Akizawa T., Takahasi K., Sugai K. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif. Organs. 1998; 22 (12): 1038– 1044. http://dx.doi.org/10.1046/j.15251594.1998.06086.x. PMID: 9876096
78. Kodama M., Hanasawa K., Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther. Apher. 1997; 1 (3): 224–227. http://dx.doi.org/10.1111/j.17449987.1997.tb00142.x. PMID: 10225743
79. Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., Lentini P., Nalesso F., Ueno T., Ranieri V.M., Ronco C. Effectiveness of polymyxin Bimmobilized fiber column in sepsis: a systematic review. Crit. Care. 2007; 11 (2): R47. http://dx.doi.org/10.1186/cc5780.PMID: 17448226
80. Nakamura T., Ebihara I., Shoji H., Ushiyama C., Suzuki S., Koide H. Treatment with polymyxin Bimmobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P selectin, platelet factor4 and betathromboglobulin. Inflamm. Res. 1999; 48 (4): 171–175. http://dx.doi.org/10.1007/s000110050442. PMID: 10344466
81. Nemoto H., Nakamoto H., Okada H., Sugahara S., Moriwaki K., Arai M., Kanno Y., Suzuki H. Newly developed polymyxin Bimmobilized fibers improve the survival of patients with sepsis. Blood Purif. 2001; 19 (4): 361–369. http://dx.doi.org/10.1159/000046966. PMID: 11574732
82. Nakamura T., Ushiyama C., Suzuki Y., Shoji H., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber for urinary albumin excretion in septic patients with trauma. ASAIO J. 2002; 48 (3): 244–248. http://dx.doi.org/10.1097/0000248020020500000008. PMID: 12058997
83. Suzuki H., Nemoto H., Nakamoto H., Okada H., Sugahara S., Kanno Y., Moriwaki K. Continuous hemodiafiltration with polymyxin B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther. Apher. 2002; 6 (3): 234–240. http://dx.doi.org/10.1046/j.15260968.2002.00416.x. PMID: 12109950
84. Tsushima K., Kubo K., Koizumi T., Yamamoto H., Fujimoto K., Hora K., KanNou Y. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory. J. Clin. Apher. 2002; 17 (2): 97–102.http://dx.doi.org/10.1002/jca.10019. PMID: 12210714
85. Tsugawa K., Koyanagi N., Hashizume M., Wada H., Ayukawa K., Akahoshi K., Tomikawa M., Sugimachi K. Results of endotoxin absorption after a subtotal resection of the small intestine and a right hemicolectomy for severe superior mesenteric ischemia. Hepatogastroenterology. 2002; 49 (47): 1303–1306. PMID: 12239931
86. Nakamura T., Ushiyama C., Suzuki Y., Inoue T., Shoji H., Shimada N., Koide H. Combination therapy with polymyxin Bimmobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillinresistant Staphylococcus aureus. J. Hosp. Infect. 2003; 53 (1): 58–63. http://dx.doi.org/10.1053/jhin.2002.1332. PMID: 12495686
87. Nakamura T., Ushiyama C., Suzuki Y., Osada S., Inoue T., Shoji H., Hara M., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber in septic patients with methicillinresistant Staphylococcus aureusassociated glomerulonephritis. Nephron. Clin. Pract. 2003; 94 (2): 33–39. http://dx.doi.org/10.1159/000071279. PMID: 12845235
88. Nakamura T., Matsuda T., Suzuki Y., Shoji H., Koide H. Polymyxin B immobilized fiber in patients with sepsis. Dial. Transplant. 2003; 32: 602–607.
89. Nakamura T., Kawagoe Y., Matsuda T., Koide H. Effect of polymyxin B immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med. 2004; 30 (9): 1838–1841. http://dx.doi.org/10.1007/s0013400423577. PMID: 15197430
90. Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Koide H. Effects of polymyxin Bimmobilized fiber on urinary NacetylBglu cosaminidase in patients with severe sepsis. ASAIO J. 2004; 50 (6): 563–567. http://dx.doi.org/10.1097/01.mat.0000142875.62592.3a. PMID: 15672789
91. Ono S., Tsujinomoto H., Matsumoto A., Ikuta S., Kinoshita M., Mochizuki H. Modulation of human leukocyte antigenDR on monocytes and CD16 on granulocytes in patients with polymyxin bimmobilized fiber. Am. J. Surg. 2004; 188 (2): 150–156. http://dx.doi.org/10.1016/j.amjsurg.2003.12.067. PMID: 15249240
92. Tsujimoto H., Ono S., Hiraki S., Majima T., Kawarabayashi N., Sugasawa H., Kinoshita M., Hiraide H., Mochizuki H. Hemoperfusion with polymyxin Bimmobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J. Endotoxin. Res. 2004; 10 (4): 229–237. http://dx.doi.org/10.1179/096805104225005814. PMID: 15373966
93. Nakamura T., Kawagoe Y., Sukuzi T., Shoji H., Ueda Y., Kobayashi N., Koide H. Changes in plasma interleukin18 by direct hemoperfusion with polymyxin Bimmobilized fiber in patients with septic shock. Blood Purif. 2005; 23 (6): 417–420. http://dx.doi.org/10.1159/000088016. PMID: 16141713
94. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., Wittebole X., De Backer D., Brett S., Marzo D., Nakamura H., John S. A pilotcontrolled study of a polymyxin Bimmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock. 2005; 23 (5): 400–405. http://dx.doi.org/10.1097/01.shk.0000159930.87737.8a. PMID: 15834304
95. Nakamura T., Ebihara I., Shimada N., Suzuki S., Ushiyama C., Shoji H., Koide H. Effects of hemoperfusion with polymyxin Bimmobilized fibre on serum neopterin and soluble interleukin2 receptor concentrations in patients with septic shock. J. Infect. 1998; 37 (3): 241–247. http://dx.doi.org/10.1016/s01634453(98)919521. PMID: 9892527
96. Nakamura T., Ebihara I., Shimada N., Koide H. Changes in plasma erythropoietin and interleukin6 concentrations in patients with septic shock after hemoperfusion and polymyxin Bimmobilized fiber. Intensive Care Med. 1998; 24 (12): 1272–1276. http://dx.doi.org/10.1007/s001340050761. PMID: 9885879
97. Nakamura T., Kawagoe Y., Matsuda T., Shoji H., Ueda Y., Tamura N., Ebihara I., Koide H. Effect of polymyxin Bimmobilized fiber on blood metalloproteinase9 and tissue inhibitor of metalloproteinase1 levels in acute respiratory distress syndrome patients. Blood Purif. 2004; 22 (3): 256–260. http://dx.doi.org/10.1159/000078494. PMID: 15148453
98. Shimada N., Nakamura T., Takayashi Y., Tanaka A., Shoji H., Sekizuka K., Ebihara I., Koide H. Effects of polymyxin Bimmobilized fiber on serum phosphate concentrations in patients with sepsis. Nephron. 2000; 86 (3): 359–360. http://dx.doi.org/10.1159/000045800. PMID: 11096302
99. Tojimbara T., Sato S., Nakajima I., Fuchinoue S., Akiba T., Teraoka S. Polymyxin Bimmobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther. Apher. Dial. 2004; 8 (4): 286–292. http://dx.doi.org/10.1111/j.15260968.2004.00166.x.PMID: 15274679
100. Ueno T., Sugino M., Nemoto H., Shoji H., Kakita A., Watanabe M. Effect over time of endotoxin adsorption therapy in sepsis. Ther. Apher. Dial. 2005; 9 (2): 128–136. http://dx.doi.org/10.1111/j.17749987.2005.00230.x. PMID: 15828924
101. Uriu K., Osajima A., Hiroshige K., Watanabe H., Aibara K., Inada Y., Segawa K., Anai H., Takagi I., Ito A., Kamochi M., Kaizu K. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin Bimmobilized fiber ameliorates systemic circulatory distur bance in patients with septic shock. Am. J. Kidney Dis. 2002; 39 (5): 937–947. http://dx.doi.org/10.1053/ajkd.2002.32767. PMID: 11979337
102. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M.; Early GoalDirected Therapy Collaborative Group. Early goaldirected therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345 (19): 1368–1377. http://dx.doi.org/10.1056/nejmoa010307. PMID: 11794169
103. Ikeda T., Ikeda K., Nagura M., Taniuchi H., Matsushita M., Kiuchi S., Kuroki Y., Suzuki K., Matsuno N. Clinical evaluation of PMXDHP for hypercytokinemia caused by septic multiple organ failure. Ther. Apher. Dial. 2004; 8 (4): 293–298. http://dx.doi.org/10.1111/j.15260968.2004.00167.x. PMID: 15274680
104. Casella G., Monti G., Terzi V., Pulici M., Ravizza A., Vesconi S. Nonconventional therapies in refractory septic shock: clinical experience with Polymyxin B. Minerva Anestesiol. 2006; 72 (1): 63–67.
105. Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 1992; 45 (7): 769–773. http://dx.doi.org/10.1016/08954356(92)90054q. PMID: 1619456
106. Kushi H., Miki T., Okamoto K., Nakahara J., Saito T., Tanjoh K. Early haemoperfusion with an immobilized polymyxin B fiber column elimi nates humoral mediators and improves pulmonary oxygenation. Crit. Care. 2005; 9 (6): R653–R661. http://dx.doi.org/10.1186/cc3815.PMID: 16280061
107. Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., Malcangi V., Petrini F., Volta G., Bobbio Pallavicini F.M., Rottoli F., Giunta F., Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23): 2445–2452. http://dx.doi.org/10.1001/jama.2009.856. PMID: 19531784
108. Vincent J.L. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1967–1968. http://dx.doi.org/10.1001/jama.2009.1606. PMID: 19903915
109. Amaral A.C. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1968–1970. http://dx.doi.org/10.1001/jama.2009.1607. PMID: 19903914
110. Kase Y., Obata T., Okamoto Y., Iwai K., Saito K., Yokoyama K., Takinami M., Tanifuji Y. Removal of 2arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial. 2008; 12 (5): 374–380. http://dx.doi.org/10.1111/j.17449987.2008.00612.x. PMID: 18937720
111. Cantaluppi V., Assenzio B., Pasero D., Romanazzi G.M., Pacitti A., Lanfranco G., Puntorieri V., Martin E.L., Mascia L., Monti G., Casella G., Segoloni G.P., Camussi G., Ranieri V.M. PolymyxinB hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008; 34 (9): 1638–1645. http://dx.doi.org/10.1007/s0013400811246. PMID: 18463848
112. Kohro S., Imaizumi H., Yamakage M., Masuda Y., Namiki A., Asai Y., Maruyama I. Anandamide absorption by direct hemoperfusion with polymixin Bimmobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J. Anesth. 2006; 20 (1): 11–16. http://dx.doi.org/10.1007/s0054000503665. PMID: 16421670
113. Matsuno N., Ikeda T., Ikeda K., Hama K., Iwamoto H., Uchiyama M., Kozaki K., Narumi Y., Kikuchi K., Degawa H., Nagao T. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther. Apher. 2001; 5 (1): 36–39. http://dx.doi.org/10.1046/j.15260968.2001.005001036.x. PMID: 11258608
114. Novelli G., Ferretti G., Poli L., Pretagostini R., Ruberto F., Perrella S.M., Levi Sandri G.B., Morabito V., Berloco P.B. Clinical results of treatment of postsurgical endotoxinmediated sepsis with polymyxinB direct hemo perfusion. Transplant. Proc. 2010; 42 (4): 1021–1024. http://dx.doi.org/10.1016/j.transproceed.2010.03.056. PMID: 20534214
115. Mori M., Onaka T., Yonezawa A., Kitagawa T., Sasaki Y., Imada K. Direct hemoperfusion using polymyxinB immobilized fiber for severe septic patients with hematological disorders: a singlecenter analysis. J. Infect. Chemother. 2014; 20 (4): 282–284. http://dx.doi.org/10.1016/j.jiac.2013.12.008. PMID: 24485325
116. Mitaka C., Fujiwara N., Yamamoto M., Toyofuku T., Haraguchi G., Tomita M. Polymyxin Bimmobilized fiber column hemoperfusion removes endotoxin throughout a 24hour treatment period. J. Crit. Care. 2014; 29 (5): 728–732. http://dx.doi.org/10.1016/j.jcrc.2014.03.031.PMID: 24798345
117. Klein D.J., Foster D., Schorr C.A., Kazempour K., Walker P.M., Dellinger R.P. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized con trolled trial. Trials. 2014; 15: 218. http://dx.doi.org/10.1186/1745621515218. PMID: 24916483
118. Cutuli S.L., Artigas A., Fumagalli R., Monti G., Ranieri V.M., Ronco C., Antonelli M.; EUPHAS 2 Collaborative Group. PolymyxinB hemoper fusion in septic patients: analysis of a multicenter registry. Ann. Intensive Care. 2016; 6 (1): 77. http://dx.doi.org/10.1186/s1361301601789. PMID: 27502196
119. Quenot J.P., Binquet C., Kara F., Martinet O., Ganster F., Navellou J.C., Castelain V., Barraud D., Cousson J., Louis G., Perez P., Kuteifan K., Noirot A., Badie J., Mezher C., Lessire H., Pavon A. The epidemiology of septic shock in French intensive care units: the prospective multicen ter cohort EPISS study. Crit. Care. 2013; 17 (2): R65. http://dx.doi.org/10.1186/cc12598. PMID: 23561510
120. Phua J., Koh Y., Du B., Tang Y.Q., Divatia J.V., Tan C.C., Gomersall C.D., Faruq M.O., Shrestha B.R., Gia Binh N., Arabi Y.M., Salahuddin N., Wahyuprajitno B., Tu M.L., Wahab A.Y., Hameed A.A., Nishimura M., Procyshyn M., Chan Y.H.; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ. 2011; 342: d3245. http://dx.doi.org/10.1136/bmj.d3245. PMID: 21669950
121. Chihara S., MasudaY., Tatsumi H., Nakano K., Shimada T., Murohashi T., Yamakage M. Early induction of direct hemoperfusion with a polymyx inB immobilized column is associated with amelioration of hemody namic derangement and mortality in patients with septic shock. J. Artif. Organs. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s1004701609229. PMID: 27469940
122. Kulabukhov V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol. Scand. 2008; 52 (7): 1024–1025. http://dx.doi.org/10.1111/j.13996576.2008.01677.x. PMID: 18494849
123. Adamik B., Zielinski S., Smiechowicz J., Kübler A. Endotoxin elimination in patients with septic shock: an observation study. Arch. Immunol. Ther. Exp. (Warsz.). 2015; 63 (6): 475– 483. http://dx.doi.org/10.1007/s0000501503488. PMID: 26093653
124. Mahlicli F.Y., Altinkaya S.A., Yurekli Y. Preparation and characterization of polyacrylonitrile membranes modified with polyelectrolyte deposition for separating similar sized proteins. J. Membr. Sci. 2012; 415–416 (1): 383–390. http://dx.doi.org/10.1016/j.memsci.2012.05.028
125. Honore P.M., Jacobs R., JoannesBoyau O., De Regt J., De Waele E., van Gorp V., Boer W., Verfaillie L., Spapen H.D. Newly designed CRRT membranes for sepsis and SIRS — a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic struc tured review. ASAIO J. 2013; 59 (2): 99–106. http://dx.doi.org/10.1097/MAT.0b013e3182816a75. PMID: 23438770
126. Mitzner S., Schneidewind J., Falkenhagen D., Loth F., Klinkmann H. Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif. Organs. 1993; 17 (9): 775–781. http://dx.doi.org/10.1111/j.15251594.1993.tb00630.x. PMID: 8240070
127. Shum H.P., Chan K.C., Kwan M.C., Yan W.W. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gramnegative bacterial infection. Hong Kong Med. J. 2013; 19 (6): 491–497. http://dx.doi.org/10.12809/hkmj133910. PMID: 23650198
128. Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock. 2005; 23 (6): 494–500. PMID:15897800
129. Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Куцук О.Н., Старостин А.В., Мельнова Н.И., Андреев С.В. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 1. Военная медицина. 2012; 3: 98–99.
130. Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Андреев С.С., Мельнова Н.И., Жук И.Н. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 2. Военная медицина. 2013; 2: 92–96.
131. Кирковский В.В., Гапанович В.Н., Третьяк Д.С., Старостин А.В., Добриянец А.И., Андреев С.В., Мельнова Н.И. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 3. Военная медицина. 2013; 3: 97–100.
132. Скворцов Н.В., Власова О.Л., Болдырев А.Г., Ларионов И.В. Оценка эффективности сорбента Сфероцелл С80 в динамическом режиме. Научнотехнические ведомости СПбГПУ. Физикоматематические науки. 2015; 2: 91–98.
133. Скворцов Н.В., Самойлов В.О., Ларионов И.В., Болдырев А.Г. Эффективный сорбент для элиминации эндотоксина в биопрепаратах генноинженерного генеза и биологических жидкостях. Научно технические ведомости СПбГПУ. Физикоматематические науки. 2013; 3: 177–181.
134. http://toxipak.ru/column/about/
135. Payen D.M., Guilhot J., Launey Y., Lukaszewicz A.C., Kaaki M., Veber B., Pottecher J., JoannesBoyau O., MartinLefevre L., Jabaudon M., Mimoz O., Coudroy R., Ferrandière M., Kipnis E., Vela C., Chevallier S., Mallat J., Robert R.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41 (6): 975–984. http://dx.doi.org/10.1007/s001340153751z. PMID: 25862039
136. Sugiura M., Mitaka C., Haraguchi G., Tomita M., Inase N. Polymyxin B immobilized fiber column hemoperfusion mainly helps to constrict peripheral blood vessels in treatment for septic shock. J. Intensive Care. 2015; 3 (1): 14. http://dx.doi.org/10.1186/s4056001500809. PMID: 25866644
137. Davankov V., Pavlova L., Tsyurupa M., Brady J., Balsamo M., Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J. Chromatogr. B. Biomed. Sci. Appl. 2000; 739 (1): 73–80. http://dx.doi.org/10.1016/s03784347(99)00554x. PMID: 10744315
Рецензия
Для цитирования:
Морозов А.С., Бессонов И.В., Нуждина А.В., Писарев В.М. Сорбенты для экстракорпорального удаления токсических веществ и молекул с нежелательной биологической активностью (обзор). Общая реаниматология. 2016;12(6):82-107. https://doi.org/10.15360/1813-9779-2016-6-82-107
For citation:
Morozov A.S., Bessonov I.V., Nuzhdina A.V., Pisarev V.M. Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review). General Reanimatology. 2016;12(6):82-107. https://doi.org/10.15360/1813-9779-2016-6-82-107
Просмотров: 1916
Послать статью по эл. почте 